1. Effect of Dapagliflozin as an Add-on Therapy to Insulin on the Glycemic Variability in Subjects with Type 2 Diabetes Mellitus (DIVE): A Multicenter, Placebo-Controlled, Double-Blind, Randomized Study
- Author
-
In Kyung Jeong, Byung Wan Lee, Soon Jib Yoo, Hyuk-Sang Kwon, Kyung Wan Min, Kun Ho Yoon, Yoon-Hee Choi, and Seung-Hwan Lee
- Subjects
Blood Glucose ,medicine.medical_specialty ,Drug/Regimen ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,030209 endocrinology & metabolism ,030204 cardiovascular system & hematology ,Hypoglycemia ,Placebo ,Gastroenterology ,Diseases of the endocrine glands. Clinical endocrinology ,law.invention ,03 medical and health sciences ,chemistry.chemical_compound ,Diabetes mellitus ,0302 clinical medicine ,Glucosides ,Randomized controlled trial ,law ,Sodium-glucose transporter 2 inhibitors ,Internal medicine ,medicine ,Humans ,Hypoglycemic Agents ,Insulin ,Benzhydryl Compounds ,Dapagliflozin ,Glycemic ,business.industry ,Blood Glucose Self-Monitoring ,Type 2 Diabetes Mellitus ,RC648-665 ,medicine.disease ,Diabetes Mellitus, Type 2 ,chemistry ,Original Article ,business - Abstract
Background Glycemic variability is associated with the development of diabetic complications and hypoglycemia. However, the effect of sodium-glucose transporter 2 (SGLT2) inhibitors on glycemic variability is controversial. We aimed to examine the effect of dapagliflozin as an add-on therapy to insulin on the glycemic variability assessed using continuous glucose monitoring (CGM) in subjects with type 2 diabetes mellitus. Methods In this multicenter, placebo-controlled, double-blind, randomized study, 84 subjects received 10 mg of dapagliflozin (n=41) or the placebo (n=43) for 12 weeks. CGM was performed before and after treatment to compare the changes in glycemic variability measures (standard deviation [SD], mean amplitude of glycemic excursions [MAGEs]). Results At week 12, significant reductions in glycosylated hemoglobin (−0.74%±0.66% vs. 0.01%±0.65%, P
- Published
- 2021